Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/33095
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDas, Nibhriti-
dc.date.accessioned2015-11-04T05:30:11Z-
dc.date.available2015-11-04T05:30:11Z-
dc.date.issued2015-11-
dc.identifier.issn0975-1009 (Online); 0019-5189 (Print)-
dc.identifier.urihttp://hdl.handle.net/123456789/33095-
dc.description701-713en_US
dc.description.abstractComplement system is a major effecter system of the innate immunity that bridges with adaptive immunity. The system consists of about 40 humoral and cell surface proteins that include zymogens, receptors and regulators. The zymogens get activated in a cascade fashion by antigen-antibody complex, antigen alone or by polymannans, respectively, by the classical, alternative and mannose binding lectin (MBL) pathways. The ongoing research on complement regulators and complement receptors suggest key role of these proteins in the initiation, regulation and effecter mechanisms of the innate and adaptive immunity. Although, the complement system provides the first line of defence against the invading pathogens, its aberrant uncontrolled activation causes extensive self tissue injury. A large number of humoral and cell surface complement regulatory protein keep the system well-regulated in healthy individuals. Complement profiling had brought important information on the pathophysiology of several infectious and chronic inflammatory disorders. In view of the diversity of the clinical disorders involving abnormal complement activity or regulation, which include both acute and chronic diseases that affect a wide range of organs, diverse yet specifically tailored therapeutic approaches may be needed to shift complement back into balance. This brief review discusses on the complement system, its functions and its importance as biomarkers and therapeutic targets for autoimmune diseases with focus on SLE and RA. en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJEB Vol.53(11) [November 2015]en_US
dc.subjectAutoimmune diseasesen_US
dc.subjectComplement receptor type 1 (CR1)en_US
dc.subjectDecay accelerating factor (DAF)en_US
dc.subjectInflammationen_US
dc.subjectMannose binding lectin (MBL) pathwayen_US
dc.subjectMembrane cofactor protein (MCP)en_US
dc.subjectMembrane attack complex (MAC)en_US
dc.subjectPolymannansen_US
dc.subjectRheumatoid Arthritis (RA)en_US
dc.subjectSystemic lupus erythematosus (SLE)en_US
dc.titleComplement and membrane-bound complement regulatory proteins as biomarkers and therapeutic targets for autoimmune inflammatory disorders, RA and SLEen_US
dc.typeArticleen_US
Appears in Collections:IJEB Vol.53(11) [November 2015]

Files in This Item:
File Description SizeFormat 
IJEB 54(1) (Erratum).pdfErratum60.35 kBAdobe PDFView/Open
IJEB 53(11) 701-713.pdfMain article376.31 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.